Matinas BioPharma Reports 2017 Second Quarter Financial Results and Reaffirms Clinical and Regulatory Strategy to Advance MAT2203 and MAT2501
Stock Information for Matinas Biopharma Holdings Inc.
Loading
Please wait while we load your information from QuoteMedia.